Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progression with prior endocrine therapy.
In the official labeling, the use of palbociclib should be accompanied with either an aromatase inhibition, no restricted to letrozole, as initial endocrine-based therapy in postmenopausal women or in man.
The breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue. This growth can spread into other parts of the body which is called metastasis. According to the location of the cancer cells, it can be categorized in ductal carcinoma and lobular carcinoma. However, other types of breast cancer include inflammatory breast cancer, Paget disease of the breast, triple negative breast cancer non-Hodgkin lymphoma and soft tissue sarcoma. In males, breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinoma.
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
University Hospital Mainz, Mainz, Germany
Samsung Medical Center, Seoul, Korea, Republic of
Vanderbilt University, Nashville, Tennessee, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Hospital Clinico Universitario de Valencia, Valencia, Spain
Hospital Universitari i Politecnic La Fe, Valencia, Spain
Instituto Valenciano de Oncología - IVO, Valencia, Spain
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University Hospital Mainz, Neurosurgery, Mainz, Germany
University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany
University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany
Duke University Medical Center, Durham, North Carolina, United States
East Carolina University, Greenville, North Carolina, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
The University of Kansas Cancer Center, Westwood, Kansas, United States
Indiana University, Indianapolis, Indiana, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
M D Anderson Cancer Center, Houston, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.